Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare disease targets.

Healx has joined forces with Ataxia UK and the US-based Friedreich's Ataxia Research Alliance (FARA) on the project, and will use its AI-powered drug discovery platform Healnet to try to find ...

The UK-based AI technology company Healx has begun a partnership with the Foundation for Angelman Syndrome Therapeutics (FAST), focusing on developing new therapies for the rare neurogenetic disorder.

Healx has established itself at the leading edge of this third generation of drug discovery by creating a suite of AI-driven methods that promise to increase the speed, scale and chance of success ...

Cambridge, UK-based healthtech startup Healx has just raised a $56 million Series B led by one of Europe's biggest investors to use artificial intelligence to treat the world's rarest diseases.

Licence: CC BY NC. Scientists at The Institute of Cancer Research, London, are working with Healx, a biotech company specialising in artificial intelligence (AI) to discover new possible ways of ...

Oxford-based Exscientia, the first to put an AI-discovered drug into human trial, is trawling through 15,000 drugs held by the Scripps research institute, in California. And Healx, a Cambridge ...